Table 1.

Patient and tumor characteristics

	N (%)
Age (N = 123)	62.1 (35.2,84.5)
Gender (N = 123)
Female	46 (37.4)
Male	77 (62.6)
Race (N = 123)
White	123 (100.0)
Other	0 (0.0)
Serious comorbidities (N = 122)*
No	115 (94.3)
Yes	7 (5.7)
Other comorbidities (N = 122)
No	34 (27.9)
Yes	88 (72.1)
Active autoimmune disease at initiation of immunotherapy (N = 123)
No	43 (35.0)
Yes	80 (65.0)
Stage at diagnosis (N = 122)
Early	21 (17.2)
Locally advanced	33 (27.0)
Metastatic	68 (55.7)
Primary site of cancer (N = 123)
NSCLC	77 (62.6)
Melanoma	18 (14.6)
SCLC	7 (5.7)
Head and neck	6 (4.9)
Urothelial	4 (3.3)
Gastrointestinal	3 (2.4)
Renal	3 (2.4)
Breast	2 (1.6)
Merkel cell	1 (0.81)
Ovarian	1 (0.81)
Sarcoma	1 (0.81)
PDL-1 expression (N = 82)
Negative	16 (19.5)
Positive	66 (80.5)
Setting of immunotherapy administration (N = 123)
Adjuvant	9 (7.3)
Locally advanced/metastatic	114 (92.7)
Line of treatment for metastatic setting (N = 113)
1st line	51 (45.1)
2nd line	53 (46.9)
3rd line and beyond	9 (8.0)
Immunotherapy agents (N = 123)
CTLA4	4 (3.3)
PD-1/PD-L1	116 (94.3)
Combination CTLA4 and PD-1	3 (2.4)
Immune checkpoint inhibitor (N = 122)
Pembrolizumab	50 (40.9)
Nivolumab	51 (41.8)
Atezolizumab	8 (6.6)
Durvalumab	5 (4.1)
Ipilimumab	4 (3.3)
Ipilimumab and nivolumab	3 (2.5)
Avelumab	1 (0.8)
Monotherapy (N = 122)
No	29 (23.8)
Yes	93 (76.2)
Combined with chemotherapy (N = 122)
No	99 (81.1)
Yes	23 (18.9)

^*Including long QT syndrome, uncontrolled or significant cardiac disease, (recent myocardial infarction, congestive heart failure, unstable angina and bradyarrhythmias)

CTLA-4 cytotoxic T-lymphocyte antigen 4, N number, NSCLC non-small cell lung cancer, PD-1 programmed cell death protein 1, PD-L1 programmed death-ligand 1, SCLC small cell lung cancer